A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date2/28/1911/7/22

Funding

  • Merck Sharp & Dohme Corporation: $135,630.00